{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:10:59Z","timestamp":1757617859843,"version":"3.44.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1038\/s41397-025-00373-2","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T21:18:44Z","timestamp":1745356724000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of pharmacodynamic genes with treatment outcomes in major depressive disorder: results from a Sardinian cohort"],"prefix":"10.1038","volume":"25","author":[{"given":"Pasquale","family":"Paribello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4175-6413","authenticated-orcid":false,"given":"Mirko","family":"Manchia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Pinna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Contu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Orr\u00f9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Upali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"El Kacemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Frau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Suprani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Corrias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Somaini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Pinna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9151-4319","authenticated-orcid":false,"given":"Claudia","family":"Pisanu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Meloni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Carta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Conversano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Mola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9491-5938","authenticated-orcid":false,"given":"Maria","family":"Del Zompo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Buson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Gennarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9463-7808","authenticated-orcid":false,"given":"Alessandra","family":"Minelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernardo","family":"Carpiniello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessio","family":"Squassina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"key":"373_CR1","unstructured":"Psychiatry.org - DSM. https:\/\/www.psychiatry.org\/psychiatrists\/practice\/dsm. Accessed 23 Aug 2024."},{"key":"373_CR2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.comppsych.2014.09.007","volume":"56","author":"M Zimmerman","year":"2015","unstructured":"Zimmerman M, Ellison W, Young D, Chelminski I, Dalrymple K. How many different ways do patients meet the diagnostic criteria for major depressive disorder? Compr Psychiatry. 2015;56:29\u201334.","journal-title":"Compr Psychiatry"},{"key":"373_CR3","unstructured":"Psychopharmacology algorithms. https:\/\/shop.lww.com\/Psychopharmacology-Algorithms\/p\/9781975151195. Accessed 23 Aug 2024."},{"key":"373_CR4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s40501-024-00316-x","volume":"11","author":"F Khorassani","year":"2024","unstructured":"Khorassani F, Jermain M, Cadiz C. Pharmacogenomic testing to guide treatment of major depressive disorder: a systematic review. Curr Treat Options Psych. 2024;11:123\u201340.","journal-title":"Curr Treat Options Psych"},{"key":"373_CR5","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1001\/jama.2022.9805","volume":"328","author":"DW Oslin","year":"2022","unstructured":"Oslin DW, Lynch KG, Shih M-C, Ingram EP, Wray LO, Chapman SR, et al. Effect of pharmacogenomic testing for drug-gene interactions on medication selection and remission of symptoms in major depressive disorder: the PRIME care randomized clinical trial. JAMA. 2022;328:151\u201361.","journal-title":"JAMA"},{"key":"373_CR6","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S2215-0366(23)00438-8","volume":"11","author":"C Veal","year":"2024","unstructured":"Veal C, Tomlinson A, Cipriani A, Bulteau S, Henry C, M\u00fch C, et al. Heterogeneity of outcome measures in depression trials and the relevance of the content of outcome measures to patients: a systematic review. Lancet Psychiatry. 2024;11:285\u201394.","journal-title":"Lancet Psychiatry"},{"key":"373_CR7","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1002\/cpt.1491","volume":"106","author":"H Zhang","year":"2019","unstructured":"Zhang H, De T, Zhong Y, Perera MA. The advantages and challenges of diversity in pharmacogenomics: can minority populations bring us closer to implementation? Clin Pharmacol Ther. 2019;106:338\u201349.","journal-title":"Clin Pharmacol Ther"},{"key":"373_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41398-023-02722-w","volume":"14","author":"D Li","year":"2024","unstructured":"Li D, Pain O, Chiara F, Wong WLE, Lo CWH, Ripke S, et al. Metabolic activity of CYP2C19 and CYP2D6 on antidepressant response from 13 clinical studies using genotype imputation: a meta-analysis. Transl Psychiatry. 2024;14:1\u20138.","journal-title":"Transl Psychiatry"},{"key":"373_CR9","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1001\/jamapsychiatry.2017.0025","volume":"74","author":"AM Chekroud","year":"2017","unstructured":"Chekroud AM, Gueorguieva R, Krumholz HM, Trivedi MH, Krystal JH, McCarthy G. Reevaluating the efficacy and predictability of antidepressant treatments: a symptom clustering approach. JAMA Psychiatry. 2017;74:370\u20138.","journal-title":"JAMA Psychiatry"},{"key":"373_CR10","doi-asserted-by":"publisher","first-page":"526","DOI":"10.3390\/ph14060526","volume":"14","author":"S Murawiec","year":"2021","unstructured":"Murawiec S, Krzystanek M. Symptom cluster-matching antidepressant treatment: a case series pilot study. Pharmaceuticals. 2021;14:526.","journal-title":"Pharmaceuticals"},{"key":"373_CR11","doi-asserted-by":"publisher","first-page":"841","DOI":"10.3390\/brainsci14080841","volume":"14","author":"AM Trevi\u00f1o-Alvarez","year":"2024","unstructured":"Trevi\u00f1o-Alvarez AM, Gluck ME, McElroy SL, Cuellar-Barboza AB. The absence of items addressing increased appetite or weight in depressive-symptom questionnaires: implications for understanding the link between major depressive disorder, antidepressants, and obesity. Brain Sci. 2024;14:841.","journal-title":"Brain Sci"},{"key":"373_CR12","first-page":"e45098","volume":"15","author":"NS Santi","year":"2023","unstructured":"Santi NS, Biswal SB, Naik BN, Sahoo JP, Rath B. Comparison of hamilton depression rating scale and montgomery-\u00e5sberg depression rating scale: baked straight from a randomized study. Cureus. 2023;15:e45098.","journal-title":"Cureus"},{"key":"373_CR13","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1159\/000457131","volume":"86","author":"N Timmerby","year":"2017","unstructured":"Timmerby N, Andersen JH, S\u00f8ndergaard S, \u00d8stergaard SD, Bech P. A systematic review of the clinimetric properties of the 6-item version of the hamilton depression rating scale (HAM-D6). Psychother Psychosom. 2017;86:141\u20139.","journal-title":"Psychother Psychosom"},{"key":"373_CR14","doi-asserted-by":"publisher","first-page":"68","DOI":"10.4103\/TPSY.TPSY_15_22","volume":"36","author":"Y-S Lin","year":"2022","unstructured":"Lin Y-S, Tsai S-J, Chen M-H. Associations between brain-derived neurotrophic factor val66Met polymorphism, melancholic feature, and treatment refractoriness in patients with treatment-resistant depression. Taiwan J Psychiatry. 2022;36:68.","journal-title":"Taiwan J Psychiatry"},{"key":"373_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-023-04756-2","volume":"23","author":"X Wang","year":"2023","unstructured":"Wang X, Wang C, Zhang Y, An Z. Effect of pharmacogenomics testing guiding on clinical outcomes in major depressive disorder: a systematic review and meta-analysis of RCT. BMC Psychiatry. 2023;23:334.","journal-title":"BMC Psychiatry"},{"key":"373_CR16","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1017\/neu.2017.6","volume":"30","author":"SD \u00d8stergaard","year":"2018","unstructured":"\u00d8stergaard SD. Do not blame the SSRIs: blame the hamilton depression rating scale. Acta Neuropsychiatrica. 2018;30:241\u20133.","journal-title":"Acta Neuropsychiatrica"},{"key":"373_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-019-2410-2","volume":"19","author":"BW Dunlop","year":"2019","unstructured":"Dunlop BW, Parikh SV, Rothschild AJ, Thase ME, DeBattista C, Conway CR, et al. Comparing sensitivity to change using the 6-item versus the 17-item Hamilton depression rating scale in the GUIDED randomized controlled trial. BMC Psychiatry. 2019;19:420.","journal-title":"BMC Psychiatry"},{"key":"373_CR18","unstructured":"PharmGKB. PharmGKB. https:\/\/www.pharmgkb.org\/. Accessed 22 July 2024."},{"key":"373_CR19","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s40261-022-01182-2","volume":"42","author":"A Carta","year":"2022","unstructured":"Carta A, Del Zompo M, Meloni A, Mola F, Paribello P, Pinna F, et al. Cost-utility analysis of pharmacogenetic testing based on CYP2C19 or CYP2D6 in major depressive disorder: assessing the drivers of different cost-effectiveness levels from an italian societal perspective. Clin Drug Investig. 2022;42:733\u201346.","journal-title":"Clin Drug Investig"},{"key":"373_CR20","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1097\/YPG.0000000000000293","volume":"31","author":"M Pinna","year":"2021","unstructured":"Pinna M, Manchia M, Pisanu C, Pinna F, Paribello P, Carta A, et al. Protocol for a pharmacogenetic study of antidepressants: characterization of drug-metabolizing profiles of cytochromes CYP2D6 and CYP2C19 in a Sardinian population of patients with major depressive disorder. Psychiatr Genet. 2021;31:186\u201393.","journal-title":"Psychiatr Genet"},{"key":"373_CR21","doi-asserted-by":"publisher","first-page":"5444","DOI":"10.1093\/nar\/19.19.5444","volume":"19","author":"DK Lahiri","year":"1991","unstructured":"Lahiri DK, Nurnberger JI. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res. 1991;19:5444.","journal-title":"Nucleic Acids Res"},{"key":"373_CR22","volume-title":"RStudio: Integrated development for R. RStudio","author":"RStudio Team","year":"2020","unstructured":"RStudio Team. RStudio: Integrated development for R. RStudio. Boston, MA: PBC; 2020."},{"key":"373_CR23","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jad.2022.12.147","volume":"325","author":"A Arnaud","year":"2023","unstructured":"Arnaud A, Benner J, Suthoff E, Werneburg B, Reinhart M, Sussman M, et al. The impact of early remission on disease trajectory and patient outcomes in major depression disorder (MDD): a targeted literature review and microsimulation modeling approach based on the sequenced treatment alternatives to relieve depression (STAR*D) study. J Affect Disord. 2023;325:264\u201372.","journal-title":"J Affect Disord"},{"key":"373_CR24","unstructured":"Clinical annotation for rs11628713 (PAPLN); citalopram; depressive disorder, major (level 3 toxicity). PharmGKB. https:\/\/www.pharmgkb.org\/clinicalAnnotation\/1444700740. Accessed 23 Aug 2024."},{"key":"373_CR25","unstructured":"Clinical annotation for rs10975641 (GLDC); citalopram or escitalopram; depressive disorder, major (level 3 Efficacy). PharmGKB. https:\/\/www.pharmgkb.org\/clinicalAnnotation\/1444705198. Accessed 23 Aug 2024."},{"key":"373_CR26","unstructured":"Clinical annotation for rs1954787 (GRIK4); antidepressants; depressive disorder (level 3 efficacy). PharmGKB. https:\/\/www.pharmgkb.org\/clinicalAnnotation\/982030381. Accessed 23 Aug 2024."},{"key":"373_CR27","unstructured":"Clinical annotation for rs6311 (HTR2A); sertraline; depressive disorder, major and sexual dysfunctions, psychological (level 4 Toxicity). PharmGKB. https:\/\/www.pharmgkb.org\/clinicalAnnotation\/1451407348. Accessed 23 Aug 2024."},{"key":"373_CR28","unstructured":"Clinical annotation for rs11144870 (rfk); citalopram or escitalopram; depressive disorder (level 3 efficacy). PharmGKB. https:\/\/www.pharmgkb.org\/clinicalAnnotation\/1183631792. Accessed 23 Aug 2024."},{"key":"373_CR29","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1017\/S0033291718003331","volume":"49","author":"TA Furukawa","year":"2019","unstructured":"Furukawa TA, Kato T, Shinagawa Y, Miki K, Fujita H, Tsujino N, et al. Prediction of remission in pharmacotherapy of untreated major depression: development and validation of multivariable prediction models. Psychol Med. 2019;49:2405\u201313.","journal-title":"Psychol Med"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41397-025-00373-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41397-025-00373-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41397-025-00373-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T12:22:00Z","timestamp":1757161320000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41397-025-00373-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,23]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["373"],"URL":"https:\/\/doi.org\/10.1038\/s41397-025-00373-2","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"type":"print","value":"1470-269X"},{"type":"electronic","value":"1473-1150"}],"subject":[],"published":{"date-parts":[[2025,4,23]]},"assertion":[{"value":"24 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Affiliation of Lisa Buson has been updated.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study adheres to the Helsinki Declaration and Good Clinical Practice guidelines and has received approval from the Ethics Committee of the University Health Agency of Cagliari (Protocol NP\/2020\/4412 on October 28, 2020). Any amendments to the protocol, informed consent, or other documents during the trial were submitted to and approved by the Ethics Committee before implementation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all subjects involved in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"10"}}